Clinical trials: Linezolid
Infections, Bacterial
A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.
GSK945237 belongs to the Bacterial Type II Topoisomerase Inhibitor (BTI) class of antibiotics. GSK945237 has demonstrated in vitro and in vivo activity against Gram positive [including methicillin resistant Staphylococcus aureus…
- Trial name
- NCT01039610
- Testing
- GSK945237, Linezolid, Moxifloxacin
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skin and Subcutaneous Tissue Bacterial Infections
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
This is a randomized, double-blind, double-dummy, multicenter, global Phase 3 study of IV to oral TR-701 FA 200 mg once daily for 6 days versus IV to oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of…
- Trial name
- NCT01421511
- Testing
- TR-701 FA, Linezolid
- Where
- 117 sites in United States, Argentina and 9 more
- Volunteers
- 666 people
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects
- Trial name
- NCT00087490
- Testing
- linezolid, vancomycin
- Where
- 126 sites in United States, Argentina and 14 more
- Volunteers
- 1,077 people
- Sponsor
- Pfizer
Acute Bacterial Skin and Skin Structure Infections
Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
The objective of this study is to evaluate the efficacy and safety of oral NXL103 vs. established treatment of acute bacterial infection in adults.
- Trial name
- NCT00949130
- Testing
- NXL103, Linezolid
- Where
- 15 sites in United States, Guatemala
- Volunteers
- 180 people
- Sponsor
- Novexel Inc
Pneumonia
Ceftobiprole in Hospital Acquired Pneumonia
The purpose of this study is to compare the clinical cure rate of ceftobiprole medocaril (the water-soluble prodrug [form] of ceftobiprole) referred to as ceftobiprole versus a comparator in the treatment of patients with…
- Trial name
- NCT00210964
- Testing
- linezolid plus ceftazidime
- Volunteers
- 781 people
- Sponsor
- Basilea Pharmaceutica
Pneumonia
Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)
This is a 1:1 ratio, randomized, double-blind, double-dummy, multicenter, global Phase 3 study of tedizolid phosphate (TR-701 FA) 200 mg intravenous (IV) once daily for 7 days versus linezolid (Zyvox®, Zyvoxid®, etc) 600 mg IV…
- Trial name
- NCT02019420
- Testing
- Tedizolid phosphate, Linezolid
- Volunteers
- 726 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia
Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin
The objective of this study is to review the local management of patients with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia treated with vancomycin or linezolid with the goal to define if any difference…
- Trial name
- NCT01561469
- Testing
- Linezolid, Vancomycin
- Volunteers
- 188 people
- Sponsor
- Pfizer
Complicated Skin and Structure Infection, Nosocomial Pneumonia
Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients
This is a retrospective, observational, non-interventional drug study using de-identified data from two administrative claims datasets. The study design and analysis will reflect the perspective of the commercially insured.
- Trial name
- NCT01363271
- Testing
- Linezolid, Vancomycin
- Volunteers
- 7,260 people
- Sponsor
- Pfizer
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP)
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
The primary objective of this study is to compare all-cause mortality at Day 14 in participants receiving cefiderocol with participants receiving the comparator, meropenem, in adults with hospital-acquired bacterial pneumonia…
- Conditions
- Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
- Trial name
- APEKS-NP (NCT03032380)
- Testing
- Cefiderocol, Meropenem, Linezolid
- Where
- 119 sites in United States, Belgium and 17 more
- Volunteers
- 300 people
- Sponsor
- Shionogi
Staphylococcal Infections
Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan)
Drug use investigation of Zyvox for patients with Methicillin-resistant Staphylococcus aureus (MRSA) infection disease. The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from…
- Trial name
- NCT00666276
- Testing
- linezolid (Zyvox)
- Volunteers
- 1,004 people
- Sponsor
- Pfizer
Skin Diseases, Bacterial
Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)
The study is now completed
- Trial name
- NCT00303550
- Testing
- Intravenous iclaprim, Intravenous linezolid
- Where
- 2 sites in United States
- Sponsor
- Arpida AG
Infectious Skin Diseases, Bacterial Skin Diseases
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections
- Conditions
- Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections
- Trial name
- NCT00646958
- Testing
- Radezolid, Linezolid
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Melinta Therapeutics, Inc.
Gram Positive Infection
Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males
Results from previous studies have been inconclusive and the effect of linezolid on cytokines remains unclear. This study is designed to evaluate the effect of linezolid on the functionality of white blood cells (neutrophils and…
- Trial name
- NCT01544673
- Testing
- linezolid
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Abscess, Wound Infection
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT01339091
- Testing
- Dalbavancin, Vancomycin / Linezolid
- Where
- 91 sites in United States, Canada and 6 more
- Volunteers
- 573 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Abscess, Wound Infection
Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The primary object is to compare the early clinical efficacy (after 48-72 hours of therapy) of dalbavancin to the comparator regimen (vancomycin with the option to switch to oral linezolid) for the treatment of patients with a…
- Conditions
- Abscess, Wound Infection, Surgical Site Infection, Cellulitis
- Trial name
- NCT01431339
- Testing
- IV Dalbavancin, Vancomycin/Linezolid
- Where
- 137 sites in United States, Bulgaria and 12 more
- Volunteers
- 739 people
- Sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
Bacterial Infections
MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection
The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections
- Trial name
- ABSSSI (NCT02269319)
- Testing
- MRX-I, Linezolid
- Volunteers
- 120 people
- Sponsor
- MicuRx
Infections, Nosocomial
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
Use of linezolid in patients with methicillin-resistant Staphylococcus aureus infections in Japan
- Trial name
- NCT00150332
- Testing
- linezolid
- Where
- 20 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Pfizer
Pneumonia, Ventilator-Associated
Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours.
- Trial name
- NCT00572559
- Testing
- Vancomycin, Linezolid
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 149 people
- Sponsor
- Pfizer
Community Acquired Pneumonia
Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate to severe community-acquired bacterial pneumonia.
- Trial name
- LEAP (NCT02559310)
- Testing
- lefamulin, Moxifloxacin, Linezolid
- Where
- 99 sites in United States, Argentina and 16 more
- Volunteers
- 551 people
- Sponsor
- Nabriva Therapeutics AG
Tuberculosis
Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult Volunteers
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of multiple doses of PNU-100480 given for 14 or 28 days.
- Trial name
- NCT00990990
- Testing
- PNU-100480, Linezolid
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Sequella, Inc.